Current Practices in Hepatic Artery Infusion (HAI) Chemotherapy: An International Survey of the HAI Consortium Research Network.
Cholangiocarcinoma
Colorectal liver metastases (CRLM)
Hepatic artery infusion
Pump
Regional therapy
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
01
03
2023
accepted:
06
07
2023
pubmed:
13
9
2023
medline:
13
9
2023
entrez:
13
9
2023
Statut:
ppublish
Résumé
An increasing number of hepatic artery infusion (HAI) programs have been established worldwide. Practice patterns for this complex therapy across these programs have not been reported. This survey aimed to identify current practice patterns in HAI therapy with the long-term goal of defining best practices and performing prospective studies. Using SurveyMonkey Thirty-six (72%) HCRN members responded to the survey. The most common intended initial indications for HAI at new programs were unresectable colorectal liver metastases (uCRLM; 100%) and unresectable intrahepatic cholangiocarcinoma (uIHC; 56%). Practice patterns evolved such that uCRLM (94%) and adjuvant therapy for CRLM (adjCRLM; 72%) have become the most common current indications for HAI at established centers. Referral patterns for pump placement differed between uCRLM and uIHC, with most patients referred while receiving second- and first-line therapy, respectively, with physicians preferring to evaluate patients for HAI while receiving first-line therapy for CRLM. Concern for extrahepatic disease was ranked as the most important factor when considering a patient for HAI. Indication and patient selection factors for HAI therapy are relatively uniform across most HCRN centers. The increasing use of adjuvant HAI therapy and overall consistency of practice patterns among HCRN centers provides a robust environment for prospective data collection and randomized clinical trials.
Sections du résumé
BACKGROUND
BACKGROUND
An increasing number of hepatic artery infusion (HAI) programs have been established worldwide. Practice patterns for this complex therapy across these programs have not been reported. This survey aimed to identify current practice patterns in HAI therapy with the long-term goal of defining best practices and performing prospective studies.
METHODS
METHODS
Using SurveyMonkey
RESULTS
RESULTS
Thirty-six (72%) HCRN members responded to the survey. The most common intended initial indications for HAI at new programs were unresectable colorectal liver metastases (uCRLM; 100%) and unresectable intrahepatic cholangiocarcinoma (uIHC; 56%). Practice patterns evolved such that uCRLM (94%) and adjuvant therapy for CRLM (adjCRLM; 72%) have become the most common current indications for HAI at established centers. Referral patterns for pump placement differed between uCRLM and uIHC, with most patients referred while receiving second- and first-line therapy, respectively, with physicians preferring to evaluate patients for HAI while receiving first-line therapy for CRLM. Concern for extrahepatic disease was ranked as the most important factor when considering a patient for HAI.
CONCLUSIONS
CONCLUSIONS
Indication and patient selection factors for HAI therapy are relatively uniform across most HCRN centers. The increasing use of adjuvant HAI therapy and overall consistency of practice patterns among HCRN centers provides a robust environment for prospective data collection and randomized clinical trials.
Identifiants
pubmed: 37702903
doi: 10.1245/s10434-023-14207-7
pii: 10.1245/s10434-023-14207-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7362-7370Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Ammori JB, Kemeny NE, Fong Y, et al. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. Ann Surg Oncol. 2013;20(9):2901–7. https://doi.org/10.1245/s10434-013-3009-3 .
doi: 10.1245/s10434-013-3009-3
Anteby R, Kemeny NE, Kingham PT, et al. Getting chemotherapy directly to the liver: the historical evolution of hepatic artery chemotherapy. J Am Coll Surg. 2021;232(3):332–8.
doi: 10.1016/j.jamcollsurg.2020.11.013
Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med. 1987;107(4):459–65. https://doi.org/10.7326/0003-4819-107-4-459 .
doi: 10.7326/0003-4819-107-4-459
Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989;7(11):1646–54. https://doi.org/10.1200/JCO.1989.7.11.1646 .
doi: 10.1200/JCO.1989.7.11.1646
Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10(7):1112–8. https://doi.org/10.1200/JCO.1992.10.7.1112 .
doi: 10.1200/JCO.1992.10.7.1112
Lorenz M, Müller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18(2):243–243. https://doi.org/10.1200/JCO.2000.18.2.243 .
doi: 10.1200/JCO.2000.18.2.243
Kemeny N, Eid A, Stockman J, et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol. 2005;91(2):97–101. https://doi.org/10.1002/jso.20286 .
doi: 10.1002/jso.20286
Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23(22):4888–96. https://doi.org/10.1200/JCO.2005.07.100 .
doi: 10.1200/JCO.2005.07.100
Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the Gastrointestinal Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23(22):4881–7. https://doi.org/10.1200/JCO.2005.05.120 .
doi: 10.1200/JCO.2005.05.120
Kemeny NE, Melendez FDH, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465–71. https://doi.org/10.1200/JCO.2008.20.1301 .
doi: 10.1200/JCO.2008.20.1301
Goéré D, Deshaies I, de Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251(4):686–91.
doi: 10.1097/SLA.0b013e3181d35983
D’Angelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261(2):353–60. https://doi.org/10.1097/SLA.0000000000000614 .
doi: 10.1097/SLA.0000000000000614
Pak LM, Kemeny NE, Capanu M, et al. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential. J Surg Oncol. 2018;117(4):634–43. https://doi.org/10.1002/jso.24898 .
doi: 10.1002/jso.24898
Lorenz M, Müller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg. 1998;228(6):756–62. https://doi.org/10.1097/00000658-199812000-00006 .
doi: 10.1097/00000658-199812000-00006
Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039–48. https://doi.org/10.1056/NEJM199912303412702 .
doi: 10.1056/NEJM199912303412702
Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol. 2002;20(6):1499–505. https://doi.org/10.1200/JCO.2002.20.6.1499 .
doi: 10.1200/JCO.2002.20.6.1499
Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005;352(7):734–5. https://doi.org/10.1056/NEJM200502173520723 .
doi: 10.1056/NEJM200502173520723
House MG, Kemeny NE, Gönen M, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011;254(6):851–6.
doi: 10.1097/SLA.0b013e31822f4f88
Groot Koerkamp B, Sadot E, Kemeny NE, et al. Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis. J Clin Oncol. 2017;35(17):1938–44. https://doi.org/10.1200/JCO.2016.71.8346 .
doi: 10.1200/JCO.2016.71.8346
Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):60–7. https://doi.org/10.1001/jamaoncol.2019.3718 .
doi: 10.1001/jamaoncol.2019.3718
Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111(2):213–20. https://doi.org/10.1002/jso.23781 .
doi: 10.1002/jso.23781
Rossi AJ, Khan TM, Luna AJ, Cercek A, Jarnagin WR, Hernandez JM. Hepatic Artery Infusion Pump (HAIP) therapy versus chemotherapy in the first-line setting for patients with unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2022;29(1):35–6. https://doi.org/10.1245/s10434-021-10279-5 .
doi: 10.1245/s10434-021-10279-5
Sumie S, Yamashita F, Ando E, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. Am J Roentgenol. 2003;181(5):1327–34. https://doi.org/10.2214/ajr.181.5.1811327 .
doi: 10.2214/ajr.181.5.1811327
Nouso K, Miyahara K, Uchida D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013;109(7):1904–7. https://doi.org/10.1038/bjc.2013.542 .
doi: 10.1038/bjc.2013.542
He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–60. https://doi.org/10.1001/jamaoncol.2019.0250 .
doi: 10.1001/jamaoncol.2019.0250
Cavnar M, Ghalambor T, Lidsky ME, et al. Considerations and barriers to starting a new HAI pump program: an international survey of the HAI Consortium Research Network. HPB. 2022;24(12):2104–11. https://doi.org/10.1016/j.hpb.2022.08.008 .
doi: 10.1016/j.hpb.2022.08.008
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309.
doi: 10.1097/00000658-199909000-00004
Buisman FE, Homs MYV, Grünhagen DJ, et al. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases—the multicenter randomized controlled PUMP trial. BMC Cancer. 2019;19(1):327–327. https://doi.org/10.1186/s12885-019-5515-6 .
doi: 10.1186/s12885-019-5515-6
Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer. 2019;109:70–83. https://doi.org/10.1016/j.ejca.2018.12.019 .
doi: 10.1016/j.ejca.2018.12.019
Morris V, Overman MJ, Jiang ZQ, et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients With BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014;13(3):164–71. https://doi.org/10.1016/j.clcc.2014.06.001 .
doi: 10.1016/j.clcc.2014.06.001
Slade JH, Alattar ML, Fogelman DR, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009;8(4):225–30. https://doi.org/10.3816/CCC.2009.n.038 .
doi: 10.3816/CCC.2009.n.038
Cercek A, Boucher TM, Gluskin JS, et al. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J Surg Oncol. 2016;114(6):655–63. https://doi.org/10.1002/jso.24399 .
doi: 10.1002/jso.24399
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N Engl J Med. 2010;362(14):1273–81. https://doi.org/10.1056/NEJMoa0908721 .
doi: 10.1056/NEJMoa0908721
Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):15. https://doi.org/10.1056/EVIDoa2200015 .
doi: 10.1056/EVIDoa2200015
Konstantinidis IT, Koerkamp BG, Do RKG, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758–65. https://doi.org/10.1002/cncr.29824 .
doi: 10.1002/cncr.29824
Holster JJ, El Hassnaoui M, Franssen S, et al. Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2022;29(9):5528–38. https://doi.org/10.1245/s10434-022-11439-x .
doi: 10.1245/s10434-022-11439-x
Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003;361(9355):368–73. https://doi.org/10.1016/S0140-6736(03)12388-4 .
doi: 10.1016/S0140-6736(03)12388-4
Kern W, Beckert B, Lang N, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol. 2001;12(5):599–603. https://doi.org/10.1023/A:1011186708754 .
doi: 10.1023/A:1011186708754
Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist. 2003;8(6):553–66. https://doi.org/10.1634/theoncologist.8-6-553 .
doi: 10.1634/theoncologist.8-6-553
Narayan RR, Datta J, Goldman DA, et al. Genomic predictors of recurrence patterns after complete resection of colorectal liver metastases and adjuvant hepatic artery infusion chemotherapy. Ann Surg Oncol. 2022;29(12):7579–88. https://doi.org/10.1245/s10434-022-12085-z .
doi: 10.1245/s10434-022-12085-z
Gholami S, Kemeny NE, Boucher TM, et al. Adjuvant hepatic artery infusion chemotherapy is associated with improved survival regardless of KRAS mutation status in patients with resected colorectal liver metastases: a retrospective analysis of 674 patients. Ann Surg. 2020;272(2):352–6. https://doi.org/10.1097/SLA.0000000000003248 .
doi: 10.1097/SLA.0000000000003248
Kemeny NE, Chou JF, Capanu M, et al. A randomized phase II trial of adjuvant hepatic arterial infusion and systemic therapy with or without panitumumab after hepatic resection of KRAS wild-type colorectal cancer. Ann Surg. 2021;274(2):248–54.
doi: 10.1097/SLA.0000000000004923
Brajcich BC, Bentrem DJ, Yang AD, et al. Short-term risk of performing concurrent procedures with hepatic artery infusion pump placement. Ann Surg Oncol. 2020;27(13):5098–106. https://doi.org/10.1245/s10434-020-08938-0 .
doi: 10.1245/s10434-020-08938-0
Grady D, Kaplan S. A lifesaving pump for cancer patients is being phased out. New York Times; 2018.